While hair loss is often the first visible indication which an individual is undergoing cancer therapy, hair normally grows back after treatment ends.
However, for many women given a chemotherapy drug widely used for breast cancer named Taxotere (generic title docetaxel), permanent hair loss has come to be a constant reminder of the battle with cancer.
To get all the latest updates of Taxotere you can choose Taxotere Hair Loss Lawsuits – Current Taxotere Lawsuit Information.
Taxotere in a Glance
Taxotere is the newest name for Sanofi’s chemotherapy medication comprising docetaxel. The drug was initially approved by the Food and Drug Administration (FDA) at 1996 and has since been extensively utilized as a treatment for prostate cancer and certain other kinds of cancer.
Though hair loss is recorded as a potential complication of Taxotere, Sanofi’s medication literature initially claimed the “hair normally grows back” after treatments are finished.
The analysis concluded that 10 to 15 percent of individuals using Taxotere (along with other goods containing docetaxel) endured long-term baldness (hair loss) as far as 3.5 years after the conclusion of therapy.
A study printed in the New England Journal of Medicine in 2010 had similar outcomes, with 9.2 % of girl patients suffering permanent baldness 10 years after the conclusion of therapy.